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Abstract: Sphingolipids (SLs), which have structural and biological responsibilities in the human
epidermis, are importantly involved in the maintenance of the skin barrier and regulate cellular
processes, such as the proliferation, di↵erentiation and apoptosis of keratinocytes (KCs). As many
dermatologic diseases, including psoriasis (PsO), intricately characterized by perturbations in these
cellular processes, are associated with altered composition and unbalanced metabolism of epidermal
SLs, more education to precisely determine the role of SLs, especially in the pathogenesis of skin
disorders, is needed. PsO is caused by a complex interplay between skin barrier disruption, immune
dysregulation, host genetics and environmental triggers. The contribution of particular cellular
compartments and organelles in SL metabolism, a process related to dysfunction of lysosomes
in PsO, seems to have a significant impact on lysosomal signalling linked to a modulation of
the immune-mediated inflammation accompanying this dermatosis and is not fully understood. It is
also worth noting that a prominent skin disorder, such as PsO, has diminished levels of the main
epidermal SL ceramide (Cer), reflecting altered SL metabolism, that may contribute not only to
pathogenesis but also to disease severity and/or progression. This review provides a brief synopsis
of the implications of SLs in PsO, aims to elucidate the roles of these molecules in complex cellular
processes deregulated in diseased skin tissue and highlights the need for increased research in the field.
The significance of SLs as structural and signalling molecules and their actions in inflammation,
in which these components are factors responsible for vascular endothelium abnormalities in
the development of PsO, are discussed.
Keywords: sphingolipid metabolism alterations; skin barrier disruption; pathogenesis of psoriasis;
lysosomal dysfunction
1. The Contribution of Selected Cellular Organelles In Lipid Metabolism
Sphingolipids (SLs) occur in the plasma membranes of all eukaryotic cells. The common element
of SLs is the unsaturated 18-carbon amino alcohol sphingosine (Sph) or one of its analogues. The fatty
acid in SLs is connected by an amide bond to the amino group of Sph. The combination of fatty acid
with sphingosine gives the basic building element of all SLs—ceramide (Cer) [1]. Cer is the centre of
SL metabolism. It is a precursor to all other types of SLs. The formation of Cer can occur via three
di↵erent pathways in the appropriate cellular organelles (Figure 1) [2]:
• de novo synthesis pathway on the cytoplasmic side of the endoplasmatic reticulum. The first
stage is the synthesis of 3-ketosphinganine, which consists of the condensation of L-serine
and palmityl-CoA catalysed by the enzyme serine palmitoyltransferase. It is a key enzyme in
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the regulation of the synthesis of 3-ketosphinganine. In the next stage, this compound is reduced to
sphinganine, which is acylated to dihydroceramide by the corresponding synthases. The last stage
of the synthesis is the oxidation of dihydroceramide to ceramide catalysed by dihydroceramide
desaturase [2–4].
• salvage pathway in lysosomes. Complex glycosphingolipids, which are important for the construction
of biological membranes, undergo cyclic catabolism. Released Cer, with the participation of acid
ceramidase, is converted into Sph. Studies show that Sph leaves the lysosome and can be metabolised
to Cer or phosphorylated to sphingosine-1-phosphate (S1P). Kitatani et al. indicate that this pathway
is responsible for 50–90% of SL biosynthesis [5].
• catabolic pathway on the cellular membrane. As a result of hydrolysis of sphingomyelin (SM) in
the presence of the corresponding enzymes, sphingomyelinases (SMases), Cer and phosphocholine
are formed. External factors, such as treatment with tumour necrosis factor ↵ (TNF-↵) or oxidative
stress [5], cause hydrolysis of SM due to activation of sphingomyelinase. The classification
of this enzyme is based on the di↵erences in optimum pH values of the catalysed reaction
and subcellular distribution; therefore, it stands out as acid SMase (aSMase; encoded by ASAH1);
neutral SMases (N-SMases; encoded by ASAH2, ASAH2B and ASAH2C) and alkaline SMase
(alk-SMase; encoded by ENPP7). Acid sphingomyelinase is located inside the cell and has
the highest activity at pH 4.0–4.5, while the neutral one is placed on the outside of the plasma
membrane and has optimal activity at pH 7.4. Moreover, it requires the presence of magnesium
(Mg2+) or manganese (Mn2+) ions as an activator. SM degradation through activity of acid
and neutral sphingomyelinase lasts a few seconds compared to de novo synthesis of Cer, whose
duration is at least several hours [5,6].
Figure 1. Key pathways of sphingolipid metabolism. De novo synthesis (1) of ceramide occurs mainly
on the outer membrane. Ketosphinganine is formed as a result of the condensation of palmityl-CoA
and serine. In the next stage, 3-ketosphinganine is rapidly converted to sphinganine. A fatty acid
residue is attached to the sphinganine molecule, resulting in the formation of dihydroceramide. The final
stage of de novo ceramide synthesis is desaturation, consisting in the formation of a double bond
between carbons 4 and 5 in a dihydroceramide molecule. Then, ceramide is transported to the Golgi
apparatus and metabolised to other sphingolipid groups. In lysosomes, the synthesis of ceramide from
sphingosine under the influence of ceramide synthase is called the salvage pathway (2), where complex
sphingolipids are digested to sphingosine, which can be transported to various cellular compartments.
Ceramide may also be synthesized in the mitochondria-associated membranes (3).
Molecules 2020, 25, 1130 3 of 20
Newly synthesized Cer can be further converted into five di↵erent lipids: ceramide-1-phosphate
(C1P), sphingomyelin (SM), ceramide phosphoethanolamine (CPE), galactosylceramide (Gal 1–10Cer)
and glucosylceramide (GlcCer) [7,8].
Further changes towards more complex lipids occur in the Golgi apparatus. Transferases,
located on the cytoplasmic side of the cisterns, attach the sugar residue to the Cer, forming cerebroside.
In this shape, it is transferred inside the Golgi apparatus to extend the carbohydrate chain by
attaching subsequent residues. Synthesis of sphingomyelin, which is based on Cer, occurs solely
within the cisternae in the cis part of the Golgi apparatus [9,10]. For further transformation into
glycosphingolipid, Cer is transported to the Golgi apparatus as an integral part of the membrane-bound
transport vesicles of the endoplasmic reticulum (ER). For the production of sphingomyelin, a specific
transporting protein (ceramide transfer protein (CERT)) is necessary to deliver Cer. For both SM
and glycosphingolipids (GSLs), the final destination is the outer layer of the cell membrane [11,12].
However, the significance of two SL derivatives, C1P and S1P, in the biochemistry of each eukaryotic
cell should be noted. Despite S1P not containing fatty acids, it is not included in the SL family, but due
to its functional and metabolic similarity, it is often discussed with them [13]. S1P synthesis requires
a sphingosine kinase (SphK), an enzyme, which phosphorylates sphingosine, while C1P is formed by
ceramide kinase (CERK), adding orthophosphate to the Cer core [13–15]. It is highly important that
both molecules have antagonistic e↵ects; therefore, they should be considered as significant metabolites
of the SL pathway [16].
The intracellular level of S1P is a result of a balance between its synthesis by SphK and its degradation
catalysed by S1P phosphatase (SPP) and S1P lyase (S1PL) [17]. SphK catalyses phosphorylation of
sphingosine to S1P and, thus, establishes balance between S1P and sphingosine. Two isoforms of
this enzyme are characterized: sphingosine kinase 1 (SphK1) and sphingosine 2 kinase (SphK2).
SphK2, unlike Sphk1, is found mainly in the cytosol, depending on the cell type, and is present in
different intracellular compartments. Both kinases can move to the cell membrane, where they catalyse
the synthesis of the pool of extracellular S1P [18].
2. Sphingolipids As A Structural Molecules - Role In Skin Barrier
Skin, the soft outer tissue of vertebrates, is a sort of “jacket” with three main functions: protection,
regulation and sensation. In humans, it covers the body, guarding the underlying muscles, bones,
ligaments and internal organs. The skin is known as the largest organ of the integumentary system.
It consists of three main layers with an origin from up to seven coats of ectodermal tissue, resulting
in a skin barrier composed of a mechanical barrier, a permeability barrier and innate and adaptive
immunity barriers [19].
Human skin acts as a first line of defence, protecting the body from unwanted environmental
influences. Although, we may be prone to regard the integument as a barrier against a hostile
environment, it should be remembered that the most important task for human skin is to create
a watertight enclosure of the body to prevent water loss. In fact, the development of such a permeable
barrier was an essential step in the evolution of life on dry land. The actual barrier is located in
the outermost layer (i.e., enucleated cells of the lipid-based stratum corneum called corneocytes),
since once this part of the skin has been removed, substances are allowed to di↵use easily into or
out of the body. One may place this fact into perspective by noting that man has a large surface area
relative to the volume enclosed by the integument. Underlying the stratum corneum is the viable
epidermis (i.e., a dynamic, constantly self-renewing tissue), in which a loss of the cells from the surface
of the stratum corneum is balanced by cell growth in the lower epidermis (i.e., cell proliferation),
followed by their maturation (i.e., cell changes in both structure, composition, synthesis and expression
of numerous di↵erent structural proteins and lipids) and di↵erentiation (i.e., cell transformation into
corneocytes) [20]. The densely packed corneocyte envelope (cellular) is chemically linked to the lipid
envelope (intracellular) of the stratum corneum, which serves as an interface between the hydrophilic
corneocytes and the lipophilic extracellular nonpolar lipids surrounding the interconnected corneocytes.
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This structure is not only a physical barrier but, also, a space for many biological and biochemical
reactions [21]. To provide a competent skin barrier, the lipids in the stratum corneum are highly
specialized. There are virtually no phospholipids in this zone, whereas the major constituents are
ceramides (belonging to a major class of lipids—sphingolipids, SLs); free fatty acids (mostly saturated
and unbranched, with the predominant two species: lignoceric acid and cerotic acid) and cholesterol
(belonging to a major sterol in the skin lipid barrier) in an approximately 1:1:1 molar ratio.
The proper function of the skin barrier requires many interactions between genetic
and immunological factors that control the expression of proteins and enzymes controlling the lipid
metabolism necessary for appropriate skin formation, composition and organization [22]. An important
role in these processes and phenomena, resulting in a properly functioning skin barrier, is attributed
to the correct metabolism of a prominent group of lipids—SLs. In the human skin, the presence of
unusual SLs based on ultra-long fatty acyl chains as well as fatty acyl groups linked on the !-end of
the N-linked acids (thereby generating a three-chain rather than a two-chain molecule) were found.
The sphingoid bases of SLs are enzymatically modified to generate a wide range of compounds,
including ceramides, S1P, ceramide-1-phosphate (C1P) and glycosphingolipids (GSLs) [21].
Ceramides, namely N-acylsphingosines, as part of extracellular lipids in the stratum corneum,
representing approximately 50% of the stratum corneum’s lipid content by weight, are important
elements of the skin barrier and are involved in the prevention of transepidermal water loss.
In the human body, ceramides are equally important inside the cell, because they regulate several
cellular processes, such as proliferation, di↵erentiation and apoptosis [22,23]. The basic structure of
this main epidermal SL is a sphingoid base with a fatty acid connected by an amide bond. Four types
of fatty acids with four types of sphingoid bases create 16 classes of Cers, being distinguished among
themselves by the length of both of these moieties. The Cers of the skin can contain sphingosine
(S) and dihydrosphingosine (dS), which are common in eukaryotic cells; phytosphingosine (P),
which is found only in some human tissues and 6-hydroxysphingosine (H), which is specific for
the epidermis [24].
Another important SL, S1P, is a phosphosphingolipid that consists of sphingosine with a phosphate
group attached at position 1 [25]. It has attracted particular attention for its e↵ect on epidermal cells,
which di↵ers from those on most other cell types. S1P inhibits proliferation of keratinocytes (KCs)
(the most abundant cells in the epidermis) and programmed cell death (apoptosis), while it induces
the di↵erentiation and migration of KCs, suggesting a role for S1P in the re-epithelialization of
wounds [26].
The skin lipids are synthesized in KCs and converted to their more polar precursors (i.e., Cers are
converted into sphingomyelins and glucosylceramides, while S1P is converted into sphingosine) [26],
which is stored in lamellar granules together with catabolic enzymes. The lamellar granules migrate
from the lower to the upper surface of the KC, merge with the plasma membrane and secrete their
contents into the intercellular space. The enzymes are activated and convert lipid precursors to barrier
lipids that finally assemble into lamellar structures that occupy the entire space between the cells [27].
Diseased skin is often characterised by reduced barrier function and altered SL formation,
composition and metabolism. Disruption of skin equipped with physical, chemical and immunological
barriers leads to an altered response of intricate cellular pathways. Loss of function of several enzymes
involved in SL metabolism leads to various forms of skin and hair defects that are often fatal [28].
Skin Barrier Dysfunction in Psoriasis
Long-term studies of the metabolism of sphingolipids (SLs) linked to the formation of the human
skin barrier have provided evidence of their role in the pathogenesis of numerous dermatologic
diseases. A very interesting fact reported in the literature was the observation of the dysregulation of
SL metabolism; in particular, quantitative and qualitative alterations of Cers and sphingosine, being
a central hub of the SL pathway, in inflammatory skin diseases, such as psoriasis (PsO) and atopic
dermatitis [28–31]. PsO, considered to develop through the crosstalk between epidermal keratinocytes
Molecules 2020, 25, 1130 5 of 20
and immunocytes, is a polygenic, chronic, inflammatory skin disease a↵ecting about 2%–3% of
the world’s population [32]. It is characterised by keratinocyte hyperproliferation, abnormal epidermal
di↵erentiation, and infiltration of immune cells into lesions. Many studies have reported various factors
contributing to the pathogenesis of psoriasis, including genetic factors (mainly genes of HLA class I);
the immune system (dendritic cell subpopulations, monocytes/macrophages, neutrophils and T cells,
especially Th1, Th17 and Th22) and environmental conditions (such as mental stress, physical injury,
infections and medications), thus recognizing it as a multifactorial disease [33]. Some reports have
led to a change in the classification of psoriasis from “skin disease” to “T lymphocyte-mediated
disease” [34]. Based on recent studies, it is worth noting that the majority of the pathogenesis of PsO
is in fact concentrated on the skin barrier, which is confirmed by the study of a single nucleotide
polymorphisms (SNPs) in the genes coding for the cornified envelope as well as enzymatic catalysis
process proteins and the observations of changes in quantitative and qualitative disturbances of
the extracellular matrix lipids.
Reports on the pathogenesis of psoriasis presenting interesting results obtained by genome-wide
association study (GWAS) has included the genetic determination of the skin barrier dysfunction.
Researchers’ attention has been focused on identification of novel genetic markers associated with
the functioning of the skin barrier in PsO. In recent times, ten epidermal genes have been documented
as psoriasis susceptibility genes [35]. As mentioned above, the role of the cornified envelope is crucial
for proper functioning of the epidermal barrier. Therefore, any abnormalities in the expression of genes
coding for proteins, which are a part of the envelope structure or participate in the enzymatic catalysis
process, may result in disturbances at various phases of keratinocyte di↵erentiation and ultimately lead
to the dysfunction of the epidermal barrier [36]. It is assumed that the decrease in the synthesis of Cer
and the malfunction of enzymes essential for its proper formation, being accompanied by a reduction
in the apoptotic signalling molecules protein kinase C-alpha (PKC-↵) and c-jun N-terminal kinase
(JNK) [37], may be correlated with the severity of psoriasis [38]. Reports on analyses of patients with
PsO have shown a significant decrease in the synthesis of Cer in skin lesions [39], while others proved
that the qualitative changes in the composition of Cer species in the epidermis [40]; in both cases, they
a↵ect the epidermal barrier. What is more, two other cases revealing the modulation in Cer formation
processes were described in the literature [41–43]. At the same time, the observations of changes in
quantitative and qualitative disturbances of the extracellular matrix lipids have showed that the level of
sphingosine is markedly higher in the psoriatic epidermis compared to skin without lesions [38,41,42].
Yet another aspect that is worthy of attention is the role of antimicrobial peptides and proteins (AMPs)
as barrier components of innate immunity defence. AMPs, of which more than 20 are known to be
present in human skin, can recruit leukocytes to the skin and stimulate them to release cytokines
and chemokines [35,43]. In patients with psoriatic lesions, there are three subclasses of AMPs, including
cathelicidin (LL37), S100 proteins (S100A7/8/9) and defensins (hBD2/3), which are highly expressed
and considered to play an important role in the pathogenesis of psoriasis [44]. Concluding the topic of
the skin barrier dysfunction in PsO, it is worth noting that current thinking supposes that psoriasis
develops as a result of the vicious cycle of barrier defect, innate immunity and adoptive defence, each
step of which may be linked genetic predisposition. In detail, this cycle comprises: (i) barrier insults by
trauma, infection and other mechanisms, (ii) abnormal response of barrier recovery, which may be due
to intracellular signalling or lipid deficiency, (iii) resulting in enormous AMPs and abnormalities of
epidermal proliferation and di↵erentiation and (iv) all of which may lead to excessive, uncontrolled
immune aberration towards Th 17/23 [35].
3. Sphingolipids As Signaling Molecules
The prefix sphingo- was used to express properties similar to the sphinx of this mysterious class
of lipids. The most important function assigned to SLs is that they act as second messengers in many
biological processes [45].
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3.1. Sphingolipid Role in Cellular Processes – Deregulation Of Keratinocytes’ Function in Psoriasis
In mammalian skin, SLs are not only an essential component of cell membranes but also are
involved in the significant biological processes, such as the aging, di↵erentiation, growth regulation
and apoptosis of epidermal cells. During these processes, SLs metabolism is continuously changing [26].
3.1.1. Cell Death In Skin Homeostasis
In the skin, apoptosis (i.e., programmed cell death) plays a key role in maintaining epidermal
homeostasis through the regulation of proliferation and formation of keratinocytes in the stratum
corneum. An important step of the stratum corneum formation is cornification, which is reported
as the conversion of living keratinocytes into dead corneocytes. Cornification is a specific
variety of apoptosis, during which the typical content of the cell is replaced by a cytoskeleton.
Crosswise interconnected proteins around the periphery of the keratinocytes form a horny envelope,
while modified and tightly packed lipids fill the intercellular spaces, forming a barrier [46].
The cornification process is impaired in psoriasis as evidenced by late cornified envelope (LCE)
gene cluster research [47]. Studies on programmed cell death in psoriasis showed a decreased
apoptosis index in psoriatic skin lesions in comparison to normal epidermis, which can be caused
by high expression of epidermal growth factor (EGFR) and interleukin-15 (IL-15RA) receptors on
keratinocytes [48]. Many studies indicate the important role of SLs in the regulation of apoptosis,
especially ceramide (Cer), which seems to be an important molecule in regulating this process [49,50].
Programmed cell death is an active process requiring the triggering of many molecular reactions
and energy expenditure. As a result of exposure of cells to stress or viral infections, a sphingomyelin-Cer
pathway may be activated. This pathway is associated with an increased concentration of Cer
in the cell, which results from the connection of a suitable ligand with a tumour necrosis factor
family receptor (TNFR), i.e., Fas ligand (FasL) or IL-1, followed by activation of aSMase or NSMase.
This enzyme cuts sphingomyelin to form Cer and phosphocholine [49]. Cer acts as a secondary lipid
transmitter that can activate specific protein targets, such as protein kinase B (Akt), protein kinase C
(PKC), mitogen-activated protein kinase (MAPK), kinase cascades stress associated protein kinase/Jun
N-terminal kinase (SAPK/JNK), Cer-activated protein phosphatase (CAPP) and phospholipase D
(PLD) [50]. Cer can also activate other cellular processes and a↵ects the activation of the internal
pathway of apoptosis by increasing the permeability of the mitochondrial membrane and release of
cytochrome c [51].
In contrast to Cer, sphingosine-1-phosphate (S1P) plays the opposite, prosurvival role by
enhancement of cell inflammation, proliferation and simultaneously resistance to apoptotic signals.
The anti-apoptotic e↵ect of S1P is associated with several cellular processes [52]. In some cell
populations, S1P may prevent apoptosis through inhibition of changes in the membrane potential of
mitochondria, thus preventing release of cytochrome c. In other cells, S1P directly stimulates MAPK,
leading to the activation of Akt kinase and inhibition of several caspase family proteins [53].
It is interesting to note that sphingosine kinase 1 (SphK1) and sphingosine 2 kinase (SphK2)
have di↵erent e↵ects on cell survival. During studies on various cell types, SphK1 hyperactivity
and increased S1P synthesis were found to promote cell survival by inducing their transition from
the G1 phase to the S phase. Compared to SphK1, the hyperactivity of SphK2 inhibits cell growth
and enhances apoptosis. In vitro studies on fibroblasts showed that overexpression of the gene
encoding SphK2 results in cell cycle arrest, activation of caspase 3 and release of cytochrome c,
which ultimately leads to apoptosis [54]. It is believed that S1P formed with the participation of SphK1
can act directly or indirectly as a negative regulator of enzymes involved in the synthesis of Cer, such as
palmitoyltransferase serine (SPT 1) or ceramide synthase (CerS). This regulation of Cer biosynthesis by
S1P can lead to inhibition of apoptosis dependent from Cer. In contrast, SPP phosphatase may also
indirectly regulate the concentration of Cer through reduction of the concentration of S1P, consequently
inducing the process of apoptosis [55,56].
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Moreover, research done by Bonhoure et al. indicated that the overexpression of SK1
(encoding sphingosine kinase 1) inhibits caspase 3 activation and cytochrome c release through
B-cell lymphoma-extra-large (BCL-XL), induced myeloid leukaemia cell differentiation protein (Mcl-1)
and Bcl-2-like protein 11 (BIM)-dependent pathways and leads to increases in the cell proliferation
rate by G1/S phase transition and increases in DNA synthesis [57]. Exogenous S1P may prevent
the intrinsic apoptotic pathway by blocking the transition of BCL2 associated agonist of cell death/apoptosis
regulator BAX (BAD/BAX) to mitochondria. However, knockdown of SK1 results in inhibition of cell
proliferation [58–64].
Acid (ACDase) and alkaline (AlkCDase) ceramidase intensify Ca2+-induced cell cycle arrest
and di↵erentiation of keratinocytes. Overexpression of AlkCDase 2 increases  1 integrin maturation
and cell adhesion. AlkCDase 2 and 3 have been shown to especially coordinate keratinocyte proliferation
and apoptosis [65].
3.1.2. Cell Proliferation
Maintaining the homeostasis of cells during their development is possible due to the precisely
regulated balance between cellular proliferation and death. The human epidermis consists of
approximately 97% keratinocytes. Within 19 days, they pass from the basal layer to the stratum
corneum accompanied by morphological changes based on their biochemical level. The basal layer
contains stem cells, which retain their constant number during division and give rise to a population
of transiently multiplying cells. These have high proliferative potential only for a limited time,
after which the cells di↵erentiate. During this process, they undergo many structural changes, including
proteomic modulation along with the reduction of the total cell biomass. Homeostasis of the epidermis
is regulated by many endogenous and exogenous factors (i.e., Ca2+ concentration, cytokines and UV
irradiation), a↵ecting the formation of the skin barrier. Moreover, the architecture of the epidermis is
largely regulated by the action of lysosomes activating signalling pathways and are responsible for
the intracellular digestion necessary for the proper di↵erentiation of keratinocytes [66–68].
In psoriatic keratinocytes, the time of cell division is shortened from 457 h to 37.5 h. Research by
Pasquali et al. revealed that, in the transcriptome of keratinocyte from psoriasis lesions, many genes
associated with the cell cycle are modulated [69]. The hyperproliferation observed in psoriasis results
from reduced apoptosis, lack of maturation of keratinocytes and incomplete keratinization with
retention of nuclei in the stratum corneum (parakeratosis). Increased proliferation may be due also
to the presence of epidermal growth factor receptor (EGFR) on the surface of keratinocytes of all
layers of the epidermis and not only on basal layer cells, as in healthy skin [70]. Disability of catabolic
processes, such as autophagy and nucleophagy, observed in keratinocytes with a psoriatic phenotype
and impaired skin barrier, arising from the altered composition of Cers and SLs, may result from
quantitative and qualitative disturbances of lysosomes and their enzymes, as we have shown in
our research. As a result of gene expression studies, we observed modulation of LAMP1 encoding
lysosomal-associated membrane protein 1 marker both in the “psoriasis-like” inflammation in vitro
model (HaCaT cells) and in the majority of patients (both psoriatic plaque (PP) and psoriatic normal
(PN) compared to nonpsoriatic normal skin (NN)) [71]. Moreover, vesicular organelles, such as
lysosomes, seem to be the obvious candidates playing an important role in the inflammatory process
of PsO, as evidenced by the gene expression and specific pathways analyses of our earlier studies [72].
In turn, our ongoing research shows significant changes in the quantity of lysosomes and other
acidic organelles, as well as dysregulation of endosomal-lysosomal signalling both at the in vitro level
(in keratinocytes with psoriatic phenotype) and at the in situ level (in the skin of psoriatic patients, both
PP and PN compared to NN). Changes in the number of lysosomes may result in the dysregulation
of selected enzymes (i.e., those involved in the Cer conversion pathway), leading to a lack of
di↵erentiation and excessive proliferation of keratinocytes, inhibition of apoptosis and disturbed skin
barrier (data not published).
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In the homeostatic state, S1P, by the activity SphK1, protects cells from Cer-induced apoptosis by
stimulation of cell proliferation and motility, while the activity of SphK2 shifts the function of S1P to
induce cell cycle arrest. In keratinocytes, S1P induces di↵erentiation but does not a↵ect proliferation
of these cells [73]. An important mechanism by which extracellularly released S1P controls cellular
metabolism is the activation of the plasma membrane localized G-protein coupled S1P receptor (S1PR).
So far, five isoforms of S1P receptors (from S1PR1 to 5) have been characterised, and all of them
are expressed in keratinocytes [74]. Many signalling pathways, such as phospholipase C (PLC),
phosphoinositide 3-kinase (PI(3)K) and protein kinase B/ras-related C3 botulinum toxin substrate 1
(Akt/Rac1), protein kinase C delta type (PKC ) and mothers against decapentaplegic homolog 3 (Smad
3), as well as release of Ca2+ ions, remain under control of S1P receptors [75]. Depending on the type
of activated receptor, S1P can both increase and decrease cell proliferation. By acting via the S1P1
and S1P3 receptors, S1P can increase cell migration. However, when S1P activates the S1P2 receptor
subtype, this process is inhibited (mainly by blocking the Akt signalling pathway, which is essential
for keratinocyte proliferation). Cell proliferation is also influenced by growth factors interacting with
S1P. Both S1P concentration and SphK activity modulate the cellular response to a number of factors,
such as platelet growth factor (PDGF), epidermal growth factor (EGF) and transforming factor growth
  (TGF- ). In addition to interacting with receptors, S1P also modulates cell activity through receptor
independent pathways, such as the modulation of histone acetylation or by polyubiquitination of
receptor interacting protein 1 (RIP1) and nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-B) activation in the RelA pathway [76,77].
On the other hand, one of the interesting and quite well-described manifestations of Cer activity
is inhibition of telomerase activity. Rebuilding telomeres is necessary for a cell to remain in the cell
cycle and repeat divisions. Meanwhile, Cer inhibits the expression of telomerase coding genes by
inactivating the transcription factor c-Myc. Thus, the cell is forced to stop divisions [78]. The balance
between Cer, sphingosine and S1P concentrations determine cell fate (death or survival) (Figure 2).
Its shift towards increased Cer and sphingosine concentrations leads to cell death. In turn, cell survival
and/or proliferation requires high S1P concentration [79].
3.1.3. Keratinocytes’ di↵erentiation
The process of keratinization of epidermal cells is a genetically conditioned, multistage biological
process involving cell division, di↵erentiation and death. The skin barrier formed in this process
not only prevents excessive water loss but also protects against the damaging e↵ects of the adverse
external environmental factors. The key signalling factor in the keratinocyte di↵erentiation, which is
essential for all stages, is the calcium ion—Ca2+. Both desmosome formation, lamellar body secretion
and activation of enzymes involved in di↵erentiation are calcium-dependent processes. Its concentration
in the extracellular space varies in the individual layers of skin, and it is around four times higher in
the upper parts of the epidermis (between 1.2 and 1.8 mM) compared to the basal layer (from 0.05
to 1.0 mM). The calcium gradient is su cient to induce cell proliferation, but further transformation
requires higher concentrations both in the extracellular space and in the cytosol [80–82]. The presence
of the cell nuclei together with the increased proliferation rate of epidermal cells occurs in the course of
psoriasis. The current state of knowledge indicates that psoriatic keratinocytes are characterised by
lack of di↵erentiation (decreased expression of K1, K10 and SIRT1 markers) compared to normal cells,
which may result from impaired calcium homeostasis [83].
SLs also a↵ect the level of calcium ions in the cell. Cer releases calcium from the ER and leads to
an increase in calcium content in the cytoplasm and mitochondria. Research on normal cultured human
keratinocytes showed that Cers are strongly involved in keratinocyte di↵erentiation by activation of
apoptosis signal-regulating kinase 1 (ASK1) and enhancing synthesis of caspase-14 [78,79].
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Figure 2. Role of the ceramide (Cer) and sphingosine-1-phosphate (S1P) in keratinocyte apoptosis
and survival. Ceramide (activated by FasL or TNF-↵) acts as a secondary lipid transmitter leads
to apoptosis through stimulation of specific protein targets, such as P38-MAPK, PKC⇣ or JNK
and inhibition of Akt kinase activity or through direct permeabilization of the mitochondrial
membrane and release of cytochrome c into the cytoplasm. S1P acts as a ceramide antagonist,
promoting cell survival by blocking a BIM-dependent signalling cascade, thus preventing the release
of cytochrome c from mitochondria or by activating Akt. Akt—protein kinase B; BAK—Bcl-2
homologous antagonist killer; BAX—apoptosis regulator BAX; Bcl-xL—B-cell lymphoma-extra-large;
BIM—Bcl-2-like protein 11; FasL—fas ligand; JNK—c-Jun N-terminal kinase; MCL-1—induced
myeloid leukaemia cell di↵erentiation protein; P38-MAPK—p38 mitogen-activated protein kinase;
PKC⇣—protein kinase C zeta type; ROS—reactive oxygen species; S1P—sphingosine-1-phosphate;
S1PR—sphingosine-1-phosphate receptor; TNF-↵—tumour necrosis factor alpha and TNFR—tumour
necrosis factor receptor.
S1P may also be involved in the regulation of calcium homeostasis in mammalian cells.
In keratinocytes, increased intracellular levels of S1P not only regulate migration and growth of
these cells but also increase Ca2+ concentration. Research suggests that S1P a↵ects intracellular levels of
Ca2+ through S1P2 and S1P3 receptors and releases Ca2+ ions mainly from the ER. S1P can also induce
release of calcium ions from permeabilised cells by a non-receptor mechanism dependent on inositol
triphosphate (IP3) [80]. The increase in the level of intracellular S1P directly mobilizes the Ca2+ ions
from thapsigargin (TG)-sensitive stores and therefore increases cytosolic Ca2+ levels [84,85]. In turn,
the increased quantity of extracellular S1P activates store-operated calcium entry (SOCE) through
a mechanism dependent on G-protein coupled receptors [86,87]. As mentioned, Sphk1 is necessary
for the synthesis of S1P and, thus, indirectly enhances gene expression of the di↵erentiation markers,
such as filaggrin (FLG) and involucrin (IVL), as studies on HaCaT (Ha = human adult, Ca = calcium
and T = temperature) keratinocytes have shown. In contrast, blocking SPHK1 leads to apoptosis in
UVB-treated keratinocytes [88].
3.2. Sphingolipid Action In Inflammation—Focus On The Molecular Mechanism Of Psoriasis
Particularly important for local immunity in the skin is the secretion of large amounts of
antimicrobial peptides, mainly  -defensins (hBDs), cathelicidins (LL-37 and CAMP) and psoriasins
(S100A7/8/9). In the early stages of psoriasis (PsO), plasmacytoid dendritic cells (pDCs) are activated
by complexes of the antibacterial peptide cathelicidin LL-37 and self-DNA/RNA in a mechanism
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similar to activation of toll-like receptor 9 (TLR9), which may explain how the host DNA becomes
a pro-inflammatory stimulus, breaking the immune tolerance in PsO. S1P, as an ER-stress signalling
molecule, strongly stimulates the expression of CAMP, while the epidermis was exposed to stress
factors (i.e., UV irradiation or attack by microorganisms) [89]. Knockdown of S1P lyase, (a polar
SL metabolite) which catabolizes S1P, promoted ER stress-induced CAMP production in cultured
keratinocytes and in mouse skin [90].
Complexes of LL37 and self-DNA released from keratinocytes activate pDCs to secrete interferon
↵/  (IFN-↵/ ). pDCs, also referred to as interferon-producing cells, belong to key cells linking the innate
and acquired immune responses. In normal conditions, pDCs, unlike myeloid dendritic cells (mDCs),
are hardly found in the tissues other than lymphatics [91]. However, in inflammation accompanying
diseases, such as lupus erythematosus or psoriasis, infiltration of the pDCs in peripheral tissues is
often observed. Within PsO lesions, they induce T cell autoproliferation and cytokine production,
mainly by T helper cells (Th cells, CD4+ cells) [92,93].
The role of Cers in the activation of dendritic cells (DCs) is constantly expanding. The first
studies were focused on an induction of DC apoptosis by C2-Cer with simultaneous downregulation
of the survival signalling pathways, such as nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-B), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt) or B-cell lymphoma-extra-large
(Bcl-xL). Another example is that the local administration of a cell permeable analogue of naturally
occurring C8-Cer results in the induction of DC maturation, appearance of major histocompatibility
complex (MHC) class I molecules and secretion of pro-inflammatory cytokines, such as IL-12p70
and TNF-↵, in response to lymphocytic choriomeningitis virus clone 13 (LCMV Cl 13) and influenza
virus infections [94]. On the other hand, S1P regulates the Th17-dependent inflammatory profile of DCs
by induction of IL-6, IL-23 and STAT3, with simultaneous repression of Th1 responses by a reduction
of IL-12p70 expression [95]. Moreover, application of fingolimod (FTY720), a structural analogue of
sphingosine, to bone marrow-derived dendritic cells (BMDCs) induces alterations of surface markers,
decline of shape indices and cell volume and surface roughness in lipopolysaccharide (LPS)-treated
cells [96].
It has been demonstrated that SLs are necessary not only in the maturation and development of
DC subtypes but also are equally important in modulating the activities of these cells. Data derived
from research using the immunomodulating drug FTY720 suggest that it a↵ects the reduction of
pro-inflammatory cytokine production, including IL-6, IL-12, TNF-↵ and monocyte chemoattractant
protein-1 (MCP-1) [96]. Moreover, S1P enhanced IL-6- and IL-23-dependent inflammation with
reduction of IL-12p70, which suggests that using S1P as a medicine may be valuable for diseases
indirectly mediated by DCs, such as psoriasis [95].
A crucial mechanism for the development of PsO is the interaction between dendritic cells
and keratinocytes. S1P has anti-inflammatory e↵ects by reducing the production of IL-12 and IL-23 in
DCs via the common subunit p40, thus inhibiting the crosstalk of DCs with activated keratinocytes.
Moreover, S1PR1 is highly important in the modulation of the cytokine profile via the mitogen-activated
protein kinase (MAPK) pathway. Another significant intercellular communication occurs between
DCs and naïve T cells. Dendritic cells migrate to regional lymph nodes, stimulating T cell activation
and maturation in response to stimuli. This is an immunological synapse model in psoriasis.
Recirculation of naïve T cells is dependent on S1P receptor signalling. In the first stage, the formation
of T lymphocytes is dependent on a strong activation signal involving the T cell receptor (TCR)
and co-stimulatory signal from the CD28 molecule, a process mediated by SMase activity. In turn,
NSMase2 generates microdomains, regulating the signal relay for signalling proteins [97]. Activation
of CD3 enhances NSMase2 production, while CD28 stimulates aSMase [98–100]. In the second stage of
T cell maturation, cytokine signals are needed. In vitro studies showed that Cer inhibits the production
of IL-2 (a cytokine that promotes naïve T cell di↵erentiation into Th1 and Th2 cells) by blocking protein
kinase C✓ (PKC✓), an e↵ector molecule of CD28 signalling, mediating activation of NF-B [101,102].
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aSMase and NSMase are important enzymes involved in synapse formation in DCs and T
cells. aSMase controls human CD4+ T cell activation by interaction with the intracellular domains
of CD3 and CD28 membrane receptors and its downstream signalling components, including
CD3-ZAP70-PLC- 1- MAPK/JNK3 and CD28-PI3K-Akt-mTOR [103]. In contrast, pharmacological
inhibition or knockdown of aSMase activity by small hairpin RNA (shRNA) blocks CD4+ T cell activation
and proliferation. In addition to CD3/CD28 receptors interaction, aSMase mediates numerous signalling
pathways. Pro-inflammatory cytokines (i.e., TNF) are capable of negating TCR signals and impair T
cell activation and functions via its type 1 receptor (TNFR1). Exposure to TNF leads to an increase in
the aSMase level with simultaneous inhibition of Ca2+ influx in Jurkat cells. Interestingly, blocking
of Ca2+ responses by TNF/TNFR1 does not occur in aSMase-deficient murine T cells. These studies
provide evidence that aSMase is strongly involved in TNF-dependent inhibition of Ca2+ and TCR
signals in T lymphocytes. Moreover, CD39 and CD161 molecules interact with aSMase, thereby
a↵ecting downstream signals dependent on STAT3 and mTOR, which leads to polarisation of Th17 cells.
Equally important, aSMase mediates Th1 responses but inhibits the Treg-dependent response [104,105].
The chronic stage of psoriasis occurs when mature dermal DCs and myeloid DCs produce IL-23
and IL-12 cytokines, which are necessary for the activation of Th1, Th17, Tc17 and Th22, which further
produce pro-inflammatory agents acting on keratinocytes that contribute to the severity of the disease.
Many studies have provided evidence of the role of individual SLs and their derivatives in the biology
of T lymphocytes at various levels [106].
In addition, SLs are also relevant in T cell migration. Each of the five di↵erent S1P receptors plays
a unique role in proliferation, tra cking and egress from the lymph nodes to the peripheral blood
and in transport from the peripheral blood to target tissue. S1P increases the synthesis of adhesion
molecules necessary for T cell recruitment and, together with S1PR4, are chemotactic for T cells. Studies
conducted on psoriatic patients taking FTY720 indicated a reduced amount of central memory T cells
and naïve T cells in the peripheral blood with simultaneous increasing amounts of T e↵ector and Treg
cells. S1P also inhibits 12-O-tetradecanoylphorbol 13-acetate (PMA)-induced proliferation of T cells
in vitro [107,108].
Acid sphingomyelinases regulate pro-inflammatory activity of CD8+ T cells by regulation of
cytotoxic granules and cytotoxic e↵ector molecule secretion. In ASM-knockout CD8+ T cells, cytokine
production, including IFN- , was decreased, indicating the key role of acid sphingomyelinases in
controlling CD8+ T cell polarisation and functions [109]. In addition to CD8+ T lymphocytes, a large
number of CD4+ T helper cells (mainly Th1 and Th17) were observed both in psoriatic skin lesions
and the peripheral blood of patients. Moreover, increased levels of cytokines, including IFN- , TNF-↵
and IL-12, were also noticed, which defined PsO as a disease mediated by T helper cells. Besides Th1
lymphocytes, which were thought to play a major role in the pathogenesis of psoriasis, the Th17/IL-23
axis is also considered to be of great importance [110]. IL-23 is produced by DCs and other antigen
presenting cells (APCs), which is required for the development and maturation of Th17 e↵ector
lymphocytes. Genetic studies have shown that IL-23p19, IL-12/23p40 and IL-23R polymorphisms are
associated with and increased risk of developing PsO [111]. IL-23, together with transforming growth
factor   (TGF- ), IL-1b, IL-6 and autocrine IL-21, is involved in the di↵erentiation and maturation
of Th17 lymphocytes, while TGF-  inhibits IL-22 production. Th17 cells a↵ect the production of
chemokines, antibacterial peptides and other pro-inflammatory cytokines, as well as the recruitment of
neutrophils, facilitating a rapid development inflammatory reaction [112].
Continuous inflammation of psoriatic skin is caused by the excessive influx of immune cells,
among which the dominant cells are neutrophils, and forms Munro’s microabscesses in the stratum
corneum of the epidermis [113]. Cer also plays an important role in monitoring the function
of neutrophils, particularly in response to TNF-↵, through control of superoxide production,
mainly by C2-Cer. C2-Cer blocks the respiratory burst of N-formylmethionine-leucyl-phenylalanine
(fMLP)-stimulated adherent neutrophils. In addition, C16- and C24-Cers also play a role in the apoptosis
mediated by caspase activation. In contrast, granulocyte macrophage colony-stimulating factor
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(GM-CSF) is an antagonist of this process, which reduces the accumulation of Cers in neutrophils
and acts as a pro-survival factor [114].
In addition to the infiltration of neutrophils and DCs, macrophages and natural killer T (NKT)
cells are also recruited into skin lesions (as well as skin without lesions, in smaller quantities) in PsO.
Dermal macrophages, activated by cytokines released from T cells or DCs, produce large amounts
of TNF-↵, IL-12 and IL-23 in response to local S1P, leading to the skin changes observed in psoriasis.
TNF-↵ signalling is orchestrated by intracellular S1P through targeting TNF receptor-associated factor
2 [115–118]. Moreover, S1P acts as a chemoattractant for monocytes, which further polarise into
macrophages. Such di↵erentiation induces these cells to secrete the proangiogenic factor prostaglandin
E2. Macrophages express S1PR on their cell surface, mainly S1PR1 and S1PR2. M2 macrophages with
anti-inflammatory phenotypes are induced by IL-4, whose secretion is mediated by S1P signalling.
Additionally, S1PR1, but not S1PR2, downregulates inducible nitric oxide synthase (iNOS) signalling
and enhances the formation of an anti-inflammatory phenotype in M2 macrophages [119]. In turn,
S1PR2 together with S1PR3 are necessary for macrophage recruitment. S1P does not have as much
impact on the phenotype of M1 cells [120].
3.3. Sphingolipids In Endothelial Function—Vascular Endothelium Abnormalities in the Development of
Psoriasis
The vascular endothelium is a source of inflammatory mediators and surface particles that
facilitate cell migration between the blood and tissues and, thus, takes part in the development
of inflammation-related diseases. It has been observed that an increase in vascular endothelium
permeability precedes the development of psoriasis and exacerbation symptoms [121]. In addition,
vascular endothelium may actively support the development of a local Th2-type response. The location of
endothelial cells makes them the first line of defence with regard to blood, and they have the first contact
with cells and substances transported from the blood to tissues. This location allows a quick response
to chemical and physical stimuli, which results in changes in the synthesis of adhesion molecules or
the secretion of factors that regulate the proliferation and migration of vascular smooth muscle cells
(VSMCs), tension in the walls of arteries and veins and the development of inflammation. Within PsO
lesions, the process of angiogenesis is excessively stimulated, and numerous vascular abnormalities
in histological and capillaroscopic examinations are found. Blood vessels of altered psoriatic skin
are widened and elongated, and their permeability increases significantly. Patients suffering from
PsO have an increased capillary mass and accelerated blood flow in skin lesions compared to normal
tissue [122,123].
Cer and S1P have antagonistic effects on vascular endothelium (Figure 3). S1P is crucial for
maintenance of vascular integrity and promotes angiogenesis directly by activating the vascular
endothelial growth factor receptor (VEGFR) or indirectly by the release of vascular endothelial growth
factor (VEGF) and interleukins (including IL-6 and IL-8) [115]. Beside VEGF, factors that stimulate
sphingosine kinase include TNF↵ and EGF [116]. S1P also activates the type 1 extracellular matrix
metalloproteinase (MT1-MMP), inducing endothelial cell migration [117]. Furthermore, the S1P-S1PR1
axis is involved in regulating the integrity of high endothelial venules (HEVs). Endothelial S1PR2 inhibits
the PI3K-Akt pathway, suppressing nitrogen oxide (NO) generation, and protects against the destruction
of adherent junctions [124]. In contrast, an increased Cer level (due to the activation of acid or neutral
sphingomyelinase) leads to increased vascular permeability and endothelial barrier dysfunction [125,126].
Cer induces endothelial cell death by activation of caspases and increasing mitochondrial permeability,
and th ey have also been linked to growth arrest, cytoskeleton rearrangements and, consequently,
senescence of endothelial cells [127].
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Figure 3. Role of ceramide (Cer) and sphingosine-1-phosphate (S1P) in the functions of vascular
endothelium. S1P is necessary for maintenance of proper vascular integrity and promotion of
angiogenesis. It is also a molecule that activate the migration of endothelial cells and protect adherent
junctions. Cer is involved in programmed endothelial cell death, senescence and cell cycle arrest,
leading to increased vascular permeability endothelial barrier dysfunction.
4. Conclusions
The discoveries made in recent decades have demonstrated the key role of SLs in cell signalling
and cellular fate control through processes such as di↵erentiation, proliferation and programmed cell
death. In the skin, SL metabolites also act as bioactive molecules involved in the control of epidermal
and immune cell signalling. Disorders of their metabolism underlie many pathological conditions,
including dermatological and immunological diseases. Psoriasis (PsO) is a disease with a multifactorial
nature, which means its exposure and severity are not only dependent on both a genetic predisposition
and disturbances of the immune system but also on environmental impact. As a result of long-term
overproduction of pro-inflammatory cytokines and the influx of T cells into the skin, there is excessive
activation and overgrowth of keratinocytes, resulting in the formation of PsO plaques with painful
and reddened changes. In the case of psoriasis, SLs act on many levels, which proves their multiple
functions in the pathogenesis process, constituting the full picture of the disease. Their quantitative
imbalance not only leads to skin barrier damage but also a↵ect migration and maturation of T
lymphocytes, activation of DCs or action of neutrophils, macrophages and natural killer T (NKT) cells.
They are also an inherent factor for the proper structure and function of the vascular endothelium.
The pathogenesis of psoriasis is a complicated process and still subject to the extension of current
knowledge, where the development of lipidomics will contribute to understanding many aspects
and mechanisms leading to the development of the disease. In addition to the fact that SLs perform
multiple functions in the pathogenesis process in psoriasis, another level regarding the role of these
compounds may be the use of their characteristics as a complementary or alternative way or remedy
in the choice of treatment. In this light, for example, study of the e cacy and safety of ponesimod
(a selective modulator of the S1P receptor 1) suggested that sphingolipid metabolism may become
a new target for the pharmacological treatment of psoriasis [20]. It is also known that proper treatment
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of psoriasis is the best strategy for preventing it from spreading. Perhaps in the future this approach
will prove to be even helpful in assessing the risk of this disease. The combination of all the fragmentary
information on the role of SLs can provide much evidence to extend the full picture of PsO.
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